Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](BioCryst Pharmaceuticals)"
Count: 52
Selected: 0
NCT IDTitle
NCT05453968Berotralstat Treatment in Children With Hereditary Angioedema
NCT05162066BCX9930 for the Treatment of C3G, IgAN, and PMN (RENEW)
NCT05116787BCX9930 for the Treatment of PNH in Subjects Not Receiving Other Complement Inhibitor Therapy
NCT05116774BCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy
NCT04933721Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies
NCT04702568A Long Term Safety Study of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04428632Oral Berotralstat Expanded Access Program
NCT04330534First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH
NCT03891420A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19
NCT03873116Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan
NCT03800173A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430
NCT03485911Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
NCT03472040A Long Term Safety Study of BCX7353 in Hereditary Angioedema
NCT03240133Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema
NCT03202784A Relative Bioavailability Study of Two Formulations of BCX7353
NCT03136237A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions
NCT02870972Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema
NCT02819102An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates
NCT02670720Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema
NCT02635724Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
NCT02448264First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers
NCT02369159Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza
NCT02319772A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430
NCT0230362612-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
NCT02218294Study to Determine How BCX4161 is Metabolized and Eliminated by the Body
NCT02125162A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161
NCT01984788Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE
NCT01407874A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
NCT01265264Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol
NCT01224795A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.
NCT01129648Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout
NCT00985127Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout
NCT00958776A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza
NCT00957996Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
NCT00705406A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza
NCT00640523Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)
NCT00610935Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza
NCT00501735Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
NCT00486980Intramuscular Peramivir for the Treatment of Uncomplicated Influenza
NCT00453999Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza
NCT00419263Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.
NCT00419081Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens
NCT00289562Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia
NCT00289549Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)
NCT00095381Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia
NCT00035022Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas
NCT00098332Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma
NCT00073944BCX-1777 in Treating Patients With Refractory Cancer
NCT00061880BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma
NCT00002237A Study of Peldesine (BCX-34) in HIV-Infected Patients